Clinical trials
Adjuvant Therapy clinical trials
Below are recruiting adjuvant therapy clinical trials, each written for real people, not researchers. We’re tracking 222 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06290687RecruitingPhase 2
Partial cystectomy with chemo for bladder cancer
This trial tests whether removing part of the bladder (partial cystectomy) along with standard chemotherapy or immunotherapy before surgery is effective for people with a specific type of bladder cancer that hasn't spread beyond the bladder.
Cleveland, OhioAges 19 years+ - NCT06692556RecruitingPhase 3
Radiation vs monitoring for high-risk skin cancer
This trial compares two strategies after surgery for a type of skin cancer (cutaneous squamous cell carcinoma) that has a high chance of coming back. One strategy gives radiation therapy to the area, while the other just watches and checks for any signs of recurrence. The goal is to see if radiation can prevent the cancer from returning.
Le Puy-en-Velay, Auvergne-Rhône-AlpesAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Daphne, AlabamaAges 18 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT06990737RecruitingPhase 2
Sentinel node biopsy for high-risk skin cancer of the head and neck
This trial is testing whether a procedure called sentinel lymph node biopsy (SLNB) can help manage high-risk skin cancer on the head and neck that has not spread to lymph nodes. It is for people whose skin cancer is considered high-risk due to features like size, depth, or location, and who are able to have surgery.
Sacramento, CaliforniaAges 18 years+ - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT06552091Recruiting
Digital self-hypnosis for hot flashes from hormone therapy
This trial tests a guided digital self-hypnosis program to help reduce hot flashes caused by hormone therapy for breast cancer. It aims to see if it can make hot flashes less frequent and bothersome.
Vandœuvre-lès-NancyAges 18 years+ - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05887102Recruiting
Program to help women take hormone pills after breast cancer
This study tests a pharmacy-based program (called PACHA) designed to help women remember and stick with hormone (endocrine) treatment after breast cancer. It may help by improving support and follow-through during the first months after starting the pills.
Québec, QuebecAges 18 years+ - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT06079333RecruitingPhase 2
Targeted therapy before and after surgery for BRAF-mutant anaplastic thyroid cancer
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
Leiden, South HollandAges 18 years+ - NCT06092892RecruitingPhase 2
Upfront targeted lymph node removal for early breast cancer
This trial is for women age 45 and older with early ER-positive breast cancer that has spread to the lymph nodes under the arm. It tests a surgery approach where the main tumor and only a few key lymph nodes (rather than many) are removed.
Los Angeles, CaliforniaAges 45 years+ - NCT06587789Recruiting
Ribociclib plus hormone therapy for high-risk breast cancer
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hangzhou, ZhejiangAges 18–80 - NCT06781996RecruitingPhase 3
Digital tool to help manage hormone therapy side effects
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
VillejuifAges 18 years+ - NCT06931769Recruiting
Optimizing treatment for stage III triple-negative breast cancer
This trial studies the best ways to give chemotherapy before and after surgery for stage III triple-negative breast cancer. It aims to improve treatment outcomes by using a personalized approach and patient-reported data.
Enschede, OverijsselAges 18 years+ - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT00353483Recruiting
Testing treatment before or after breast cancer surgery
This trial studies how different cancer treatments given before or after standard therapy affect breast cancer cells in the blood and bone marrow. It may help doctors better understand how treatments work throughout the body, not just where the tumor is.
St Louis, MissouriAges 18 years+ - NCT02394626RecruitingPhase 2
Surgery for glioblastoma that has come back
This trial studies whether operating on a brain tumor that has returned can help people with recurrent glioblastoma. It focuses on people whose scans suggest surgery is safe for important speech and movement brain areas.
InnsbruckAges 18 years+ - NCT07643012Recruiting
Daily MRI-Guided Radiation for Endometrial Cancer
This trial tests whether using MRI scans daily during pelvic radiation therapy improves treatment precision and outcomes for endometrial cancer patients who need radiation after surgery. The goal is to better target cancer while reducing side effects.
New Brunswick, New JerseyAges 18–90 - NCT03396718Recruiting
De-escalating radiation after HPV head and neck cancer surgery
This study looks at whether some people with HPV-positive throat/oropharynx cancer can safely receive a less intense form of radiation (and sometimes chemo) after surgery. It aims to reduce treatment burden while keeping the cancer under control, based on how high-risk the pathology looks.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07541079RecruitingPhase 3
Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Fountain Valley, CaliforniaAges 18 years+
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adjuvant therapy?
- Yes. Clin2 currently lists 222 recruiting adjuvant therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adjuvant therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adjuvant therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.